#United States #Class Action #New Orleans #Kahn Swick #Cytokinetics

Cytokinetics Shareholder Alert and Class Action Lawsuit

In a recent announcement, Kahn Swick & Foti, LLC (KSF) and its partner Charles C. Foti, Jr., former Attorney General of Louisiana, are reaching out to investors of Cytokinetics, Incorporated (NASDAQ: CYTK). They remind shareholders that they have until November 17, 2025, to file applications as lead plaintiffs in a class action lawsuit against the company. This notice is particularly crucial for those who suffered losses exceeding $100,000 from purchasing Cytokinetics securities between December 27, 2023, and May 6, 2025.

Understanding the Class Action

This class action lawsuit is progressing within the United States District Court for the Northern District of California. The allegations against Cytokinetics and certain executives include not disclosing critical information during the defined Class Period, potentially violating federal securities laws.

On March 10, 2025, Cytokinetics revealed that the FDA had opted not to hold an advisory committee meeting regarding the company’s New Drug Application (NDA) for its aficamten product. Following that on May 6, 2025, the company disclosed that it had engaged in multiple discussions with the FDA about safety monitoring, yet chose to submit the NDA without a Risk Evaluation and Mitigation Strategy. Consequently, this reliance on other measures impacted the company's share price significantly, leading to a decline recorded at $33.04 per share on the following day, May 7, 2025.

Your Rights as an Investor

If you are among the shareholders affected by these developments and would like to understand your legal rights, KSF offers assistance at no charge. Investors can contact Lewis Kahn, the Managing Partner, toll-free at 1-877-515-1850 or via email at [email protected]. More information can also be found on KSF’s website, which provides resources for those considering serving as lead plaintiffs in this class action lawsuit, emphasizing the importance of filing by the stated deadline.

About Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC is recognized as one of the leading boutique securities litigation law firms in the United States. In the past year, their work led them to receive accolades from SCAS, ranking them within the top 10 firms nationally based on total settlement value. They cater extensively to both institutional and retail investors, focusing on recovering losses due to corporate misdeeds and other financial malfeasance.

With offices spread across key locations including New York, California, Louisiana, and other states, KSF is well positioned to offer robust representation to investors nationwide. For those interested in learning more about the firm or how they might assist in other matters, please visit www.ksfcounsel.com or connect with them through various social media platforms.

Conclusion

This alert serves as an important reminder for investors with significant losses in Cytokinetics. Taking action before the November deadline is vital for recovery opportunities through legal means. Understanding your rights and the implications of the ongoing class action provides a pathway toward potential restitution. As circumstances evolve, staying informed through reliable legal counsel is essential for all affected investors.